Sprint Bioscience AB (publ) (STO:SPRINT)

Sprint Bioscience AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	84.49	91.74	-18.28	-0.44	-60.17	-25.08
Depreciation & Amortization	1.08	1.07	0.96	0.45	0.62	0.59
Other Operating Activities	-1.64	-	-	-	-	-0.06
Change in Accounts Receivable	3.36	6.02	-4.25	-2.55	-0.09	-0.1
Change in Accounts Payable	-2.03	-1.04	-0.23	2.02	0.84	-0.43
Change in Other Net Operating Assets	-15.49	-14.26	-1.56	23.39	-0.25	-15.04
Operating Cash Flow	69.76	83.53	-23.36	22.87	-59.05	-40.12
Capital Expenditures	-0.07	-0.09	-1.3	-2.45	-	-2.71
Investment in Securities	0.04	0.04	-	-	-	-
Investing Cash Flow	-0.03	-0.05	-1.3	-2.45	-	-2.71
Short-Term Debt Issued	-	-	-	-	-	10
Total Debt Issued	-	-	-	-	-	10
Net Debt Issued (Repaid)	-	-	-	-	-	10
Issuance of Common Stock	23.45	23.45	-	0.02	22.41	88.8
Other Financing Activities	-5.28	-5.28	-0.23	-	-4.51	-12.41
Financing Cash Flow	18.17	18.17	-0.23	0.02	17.9	86.39
Foreign Exchange Rate Adjustments	1.64	-	-	-	-	-
Net Cash Flow	89.54	101.65	-24.88	20.44	-41.15	43.57
Free Cash Flow	69.7	83.44	-24.65	20.42	-59.05	-42.82
Free Cash Flow Margin	45.52%	49.85%	-37.27%	39.50%	-71149.40%	-122.26%
Free Cash Flow Per Share	0.69	0.90	-0.35	0.29	-1.40	-1.49
Cash Interest Paid	6.21	6.21	0.04	0.39	0.11	0.37
Levered Free Cash Flow	42	52.4	-18.16	19.99	-36.81	-23.87
Unlevered Free Cash Flow	42	52.67	-18.14	19.99	-36.81	-23.7
Change in Working Capital	-14.16	-9.28	-6.04	22.86	0.5	-15.57

Source: S&P Global Market Intelligence. Standard template. Financial Sources.